AI Article Synopsis
- The study examined the epidemiology, management, and economic impact of myasthenia gravis using data from about 12 million people in Italy from 2011 to 2018.
- It found that the prevalence of myasthenia gravis in 2018 ranged from 13.5 to 29.3 cases per 100,000 people, with a population estimate of 8,190 to 17,728 affected individuals.
- Treatment indications revealed high usage of pyridostigmine (84%) and corticosteroids (54%), with healthcare costs for myasthenia gravis patients being four times greater than the general population, significantly increasing for those experiencing exacerbations.
Article Abstract
The purpose of this study was to investigate the epidemiology, management, and economic burden of myasthenia gravis in settings of real clinical practice. The analysis used administrative databases covering around 12 million subjects across Italy and included all adult patients with hospitalization discharge diagnosis or active exemption code for myasthenia gravis or with ≥1 pyridostigmine prescription from 2011 to 2018. The estimated prevalence of myasthenia gravis during 2018 was in the range 13.5-29.3/100,000 people (depending on the criteria applied), corresponding to 8190-17,728 alive patients, when reproportioning data to the entire Italian population. Overall 4397 patients with myasthenia gravis (mean age 61.7 years, 46.6% males) were included. A large pyridostigmine use was observed (84.0%-46.8% from 1st to 3rd year of follow-up), followed by corticosteroids (54.5%-44.6% from 1st to 3rd year of follow-up) and non-steroidal immunosuppressants (16% over follow-up). Total direct healthcare costs for myasthenia gravis were 4-times higher than those of the general population (€3771 and €869, respectively), and up to 9-fold increased when considering patients with exacerbation (€7827). These findings showed the epidemiologic burden of myasthenia gravis and the complexity of the therapeutic management for the affected patients, with large use of treatments and elevated healthcare expenditures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238888 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2023.e16367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Analyses of the risk factors of delayed extubation after extended thymectomy in patients with myasthenia gravis].
Zhonghua Nei Ke Za Zhi
January 2025
Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing100053, China.
To explore the risk factors of delayed extubation after expanded thymectomy in patients with myasthenia gravis. Patients with myasthenia gravis who underwent expanded thymectomy from May 2021 to January 2024 and were admitted to Intensive Care Unit (ICU) after surgery were retrospectively analyzed. Patients were divided in to the delayed extubation and successful extubation according to the length of mechanical ventilation whether exceeding than 48 hours.
View Article and Find Full Text PDFUnusual outcome of treatment of thymoma with immunotherapy: case report.
Mediastinum
November 2024
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).
View Article and Find Full Text PDFSurgical management of thymic tumors: a narrative review with focus on robotic-assisted surgery.
Mediastinum
November 2024
University of Bern, Bern, Switzerland.
Background And Objective: Thymic epithelial tumors, including thymomas and thymic carcinomas, represent the most common mediastinal tumors and account for up to 50% of all anterior mediastinal tumors. For early stages of these thymic tumors, complete resection of the entire thymus is the recommended treatment. The transition from open surgery to video-assisted thoracoscopic surgery (VATS) and recently to robotic-assisted thoracic surgery (RATS) has fundamentally altered the treatment of thymic tumors.
View Article and Find Full Text PDFCurrent immunotherapy for thymic epithelial tumors: a narrative review.
Mediastinum
October 2024
Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Background And Objective: Thymic epithelial tumors (TETs) are the most common neoplasm of the prevascular mediastinal compartment and are characterized by their rarity and variable clinical presentation. The present study aimed to explore the current management of patients with TET with a special focus on immunotherapy for advanced disease.
Methods: Relevant studies published between 1981 and 2024 were searched in PubMed using search terms "Thymoma", "Thymic cancer", "Myasthenia gravis", "Radiation therapy", "Surgery", and "Immunotherapy".
Isolated Ophthalmoplegia: An Uncommon Presentation of Anti-glutamic Acid Decarboxylase 65 (Anti-GAD65) Neurological Syndrome.
Cureus
December 2024
Neurology, Tecnológico de Monterrey, Monterrey, MEX.
Isolated ophthalmoplegia as an anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody-associated neurological syndrome is rare. We present a case of a 22-year-old pregnant Hispanic female patient who presented initially with a left oculomotor nerve palsy following an emergency department (ED) visit for migraine headache. Brain imaging was done with no important findings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!